AI in early Drug Discovery: From Promise to Practice
In this webinar, Jeff Blaney (Senior Director of Discovery Chemistry, Genentech), Darren Green (Head of Cheminformatics & Data Science, GlaxoSmithKline), Julian Levell (Head of Discovery, New Equilibrium Biosciences), Matthew Segall (CEO, Optibrium) discuss the state of AI in early drug discovery from hit to preclinical candidate and share their experiences with and expectations of AI, including predictive modelling, synthesis prediction, and generative chemistry. Hear about the successes of AI drug discovery and an outlook on what AI needs to achieve to really transform the industry.
To hear the narration, please increase your speaker volume.
INTERESTED IN AI IN DRUG DISCOVERY?
Cerella™ is a unique artificial intelligence platform which supports medicinal chemists and other discovery scientists, escalating the success rate and advances small molecule drug discovery from working with early hits to nominating preclinical candidates.
Cerella’s AI platform is proven to overcome limitations in drug discovery data, confidently deliver results, seamlessly integrate with your med chem software platforms and help you and your colleagues increase the success rate of your projects.